Health AI Central
Share:
Peer-Reviewed Publication
Ann Am Thorac Soc2026August 5, 2026Journal Article

Pulmonary Outcomes in People with Cystic Fibrosis who Stop Chronic Daily Therapies: The HERO-2 Study.

Cynthia D Brown1, Kevin J Psoter2, Kathryn A Sabadosa3, Joshua S Ostrenga3, Bradley H Rosen1, Georgene Hergenroeder4, Lisa Bendy5, Connie Zhang6, Nell Meosky Luo6, Clement L Ren4
1Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
2Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.
3Cystic Fibrosis Foundation, Bethesda, MD, USA.
4Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
5Riley Hospital for Children, Indianapolis, IN, USA.
6Folia Health, Cambridge, MA, USA.
PubMed DOI

Abstract

RATIONALE: Given improvement in symptoms and lung function in people with cystic fibrosis (CF) taking elexacaftor/tezacaftor/ivacaftor (ETI), there is increasing interest in de-escalation of care although the effect on outcomes remains unknown. OBJECTIVES: To determine if self-reported discontinuation of chronic daily therapies (CDT) is associated with changes in pulmonary exacerbations and lung…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.